Fracture events associated with GLP-1 receptor agonists in FDA adverse events reporting system
Acta Diabetologica · 2024
DOI: 10.1007/s00592-024-02415-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Diabetologica, 2024. Verfasst von Yao Xiao und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Endocrinology Research Center, Xiangya Hospital of Central South University, Changsha, 410008, Hunan, China. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Adverse Drug Reaction Reporting Systems, Fractures, Bone, Hypoglycemic Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 61 Literaturangaben.
Themen: Patientensicherheit
Abstract (Originalsprache)
AIMS: Diabetes patients are at a higher risk of fractures, and glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been suggested to positively impact on bone metabolism. We aim to provide a comprehensive assessment of fracture events associated with GLP-1RAs based on pharmacovigilance data. METHODS: In this study, fracture-related adverse events (AEs) associated with GLP-1RAs and other commonly used glucose-lowering drugs were identified from Food and Drug Administration Adverse Event Reporting System (FAERS) database (2004-2022). The reporting odds ratio (ROR) and adjusted ROR (adj. ROR) were used to compare the reporting of fracture-related AEs associated with insulin, GLP-1RAs, and Non GLP-1RAs, in patients with diabetes through two scenarios. This involved separately comparing each glucose-lowering drug to all other medications used in diabetic patients and reiterating after excluding insulin cases. RESULTS: A total of 490,107 AE reports for patients with diabetes were identified and 98, 625 of them were for GLP-1RAs. Among all diabetes drugs, GLP-1RAs had the lowest reporting of any fracture-related AEs [adj. ROR = 0.44 (0.40-0.47)], consistent across osteoporotic fracture [adj. ROR = 0.39 (0.34-0.45)] and hip fracture [adj. ROR = 0.34 (0.28-0.41)]. Among GLP-1RA agents, albiglutide was associated with the lowest adj. ROR [0.11 (0.05-0.21)] for any fracture-related AEs. After excluded all insulin reports, GLP-1RAs retained a significantly lower adj. ROR towards any fracture [adj. ROR = 0.45 (0.40-0.50)], osteoporotic fracture [adj. ROR = 0.44 (0.37-0.52)], and hip fracture [adj. ROR = 0.43 (0.33-0.54)]. CONCLUSION: In a real-world pharmacovigilance setting, GLP-1RAs were associated with lower reporting of fracture-related AEs, indicating the protective effect of GLP-1RAs against fractures.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Endocrinology Research Center, Xiangya Hospital of Central South University, Changsha, 410008, Hunan, China.
- Department of Orthopedics, Xiangya Hospital of Central South University, Changsha, 410008, Hunan, China. Xiaowf11@sina.com.
- National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, 410008, Hunan, China. Xiaowf11@sina.com.
Zitieren
APA
Xiao, Y., Zhou, M., & Xiao, W. (2024). Fracture events associated with GLP-1 receptor agonists in FDA adverse events reporting system. Acta Diabetologica. https://doi.org/10.1007/s00592-024-02415-w
Vancouver
Xiao Y, Zhou M, Xiao W. Fracture events associated with GLP-1 receptor agonists in FDA adverse events reporting system. Acta Diabetologica. 2024. doi:10.1007/s00592-024-02415-w
BibTeX
@article{Xiao2024,
author = {Xiao, Yao and Zhou, Min and Xiao, Wenfeng},
title = {Fracture events associated with GLP-1 receptor agonists in FDA adverse events reporting system},
journal = {Acta Diabetologica},
year = {2024},
doi = {10.1007/s00592-024-02415-w}
}
EUVIMED